段天兵,向定成

• 1:广州军区广州总医院老年医学科
• 2:广州军区广州总医院心内科

摘要(Abstract)：

<正>诱导冠状动脉充血,尽可能消除阻力血管的影响,是研究冠状动脉功能的有效方法[1]。运动、堵塞冠状动脉和充血药物均能诱导冠状动脉充血,但运动不适用于活动耐量有限的人群;堵塞冠状动脉可以诱发极好的充血效应,但存在血管损伤风险[2]。因此,药物诱导最大充血反应是一种广泛应用于导管室的方法。理想的充血药物具有快速起效、半

关键词(KeyWords)： 冠状动脉循环;充血药物;腺苷三磷酸

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 段天兵,向定成

参考文献(References)：

• [1]Drenjancevic I,Koller A,Selthofer-Relatic K,et al.Assessment of coronary hemodynamics and vascular function.Prog Cardiovasc Dis,2015,57(5):423-430.
• [2]Jeremias A,Filardo SD,Whitbourn RJ,et al.Effects of intravenous and intracoronary adenosine 5'-triphosphate as compared with adenosine on coronary fl ow and pressure dynamics.Circulation,2000,101(3):318-323.
• [3]Bookstein JJ,Higgins CB.Comparative effi cacy of coronary vasodilatory methods.Invest Radiol,1977,12(2):121-127.
• [4]Wilson RF,White CW.Intracoronary papaverine:an ideal coronary vasodilator for studies of the coronary circulation in conscious humans.Circulation,1986,73(3):444-451.
• [5]Christensen CW,Rosen LB,Gal RA,et al.Coronary vasodilator reserve.Comparison of the effects of papaverine and adenosine on coronary flow,ventricular function,and myocardial metabolism.Circulation,1991,83(1):294-303.
• [6]Kern MJ,Deligonul U,Tatineni S,et al.Intravenous adenosine:continuous inf usion and low dose bolus administration f or determination of coronary vasodilator reserve in patients with and without coronary artery disease.J Am Coll Cardiol,1991,18(3):718-729.
• [7]van der Voort PH,van Hagen E,Hendrix G,et al.Comparison of intravenous adenosine to intracoronary papaverine for calculation of pressure-derived fractional fl ow reserve.Cathet Cardiovasc Diagn,1996,39(2):120-125.
• [8]De Bruyne B,Pijls NH,Barbato E,et al.Intracoronary and intravenous adenosine 5'-triphosphate,adenosine,papaverine,and contrast medium to assess fractional flow reserve in humans.Circulation,2003,107(14):1877-1883.
• [9]Egashira K,Inou T,Hirooka Y,et al.Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms.N Engl J Med,1993,328(23):1659-1664.
• [10]Takeuchi M,Nohtomi Y,Kuroiwa A.Intracoronary papaverine induced myocardial lactate production in patients with angiographically normal coronary arteries.Cathet Cardiovasc Diagn,1996,39(2):126-130.
• [11]Wilson RF,White CW.Serious ventricular dysrhythmias after intracoronary papaverine.Am J Cardiol,1988,62(17):1301-1302.
• [12]Kern MJ,Deligonul U,Serota H,et al.Ventricular arrhythmia due to intracoronary papaverine:analysis of QT intervals and coronary vasodilatory reserve.Cathet Cardiovasc Diagn,1990,19(4):229-236.
• [13]Vrolix M,Piessens J,De Geest H.Torsades de pointes after intracoronary papaverine.Eur Heart J,1991,12(2):273-276.
• [14]Inoue T,Asahi S,Takayanagi K,et al.QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine.Cardiology,1994,84(1):9-13.
• [15]Layland J,Carrick D,Lee M,et al.Adenosine:physiology,pharmacology,and clinical applications.JACC Cardiovasc Interv,2014,7(6):581-591.
• [16]Drury AN,Szent-Gy?rgyi A.The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart.J Physiol,1929,68(3):213-237.
• [17]Belhassen B,Pelleg A.Electrophysiologic effects of adenosine triphosphate and adenosine on the mammalian heart:clinical and experimental aspects.J Am Coll Cardiol,1984,4(2):414-424.
• [18]Pijls NH,De Bruyne B,Peels K,et al.Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses.N Engl J Med,1996,334(26):1703-1708.
• [19]Leone AM,Porto I,De Caterina AR,et al.Maximal hyperemia in the assessment of fractional fl ow reserve:intracoronary adenosine versus intracoronary sodium nitroprusside versus intravenous adenosine:the NASCI(Nitroprussiato versus Adenosina nelle Stenosi Coronariche Intermedie)study.JACC Cardiovasc interv,2012,5(4):402-408.
• [20]Seo MK,Koo BK,Kim JH,et al.Comparison of hyperemic effi cacy between central and peripheral venous adenosine infusion for fractional flow reserve measurement.Circ Cardiovasc Interv,2012,5(3):401-405.
• [21]Lindstaedt M,Bojara W,Holland-Letz T,et al.Adenosine-induced maximal coronary hyperemia for myocardial fractional fl ow reserve measurements:comparison of administration by femoral venous versus antecubital venous access.Clin Res Cardiol,2009,98(11):717-723.
• [22]Jeremias A,Whitbourn RJ,Filardo SD,et al.Adequacy of intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional fl ow reserve measurements.Am Heart J,2000,140(4):651-657.
• [23]Murtagh B,Higano S,Lennon R,et al.Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment.Am Heart J,2003,146(1):99-105.
• [24]Casella G,Leibig M,Schiele TM,et al.Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional fl ow reserve?Am Heart J,2004,148(4):590-595.
• [25]Yoon MH,Tahk SJ,Yang HM,et al.Comparison of the intracoronary continuous infusion method using a microcatheter and the intravenous continuous adenosine infusion method for inducing maximal hyperemia for fractional flow reserve measurement.Am Heart J,2009,157(6):1050-1056.
• [26]De Luca G,Venegoni L,Iorio S,et al.Effects of increasing doses of intracoronary adenosine on the assessment of fractional flow reserve.JACC Cardiovasc Interv,2011,4(10):1079-1084.
• [27]Mc Geoch RJ,Oldroyd KG.Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology.Catheter Cardiovasc Interv,2008,71(2):198-204.
• [28]Kern MJ,Lerman A,Bech JW,et al.Physiological assessment of coronary artery disease in the cardiac catheterization laboratory:a scientif ic statement f rom the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization,Council on Clinical Cardiology.Circulation,2006,114(12):1321-1341.
• [29]Pijls NH,Sels JW.Functional measurement of coronary stenosis.JAm Coll Cardiol,2012,59(12):1045-1057.
• [30]Cerqueira MD,Verani MS,Schwaiger M,et al.Safety profi le of adenosine stress perfusion imaging:results from the Adenoscan Multicenter Trial Registry.J Am Coll Cardiol,1994,23(2):384-389.
• [31]Bernhardt P,Steffens M,Kleinertz K,et al.Safety of adenosine stress magnetic resonance imaging using a mobile cardiac magnetic resonance system.J Cardiovasc Magn Reson,2006,8(3):475-478.
• [32]Burki NK,Dale WJ,Lee LY.Intravenous adenosine and dyspnea in humans.J Appl Physiol,2005,98(1):180-185.
• [33]Yamada H,Azuma A,Hirasaki S,et al.Intracoronary adenosine5'-triphosphate as an alternative to papaverine f or measuring coronary fl ow reserve.Am J Cardiol,1994,74(9):940-941.
• [34]Sonoda S,Takeuchi M,Nakashima Y,et al.Safety and optimal dose of intracoronary adenosine 5'-triphosphate for the measurement of coronary fl ow reserve.Am Heart J,1998,135(4):621-627.
• [35]Shiode N,Kato M,Nakayama K,et al.Effects of adenosine triphosphate on human coronary circulation.Intern Med,1998,37(10):818-825.
• [36]Gerber KH,Higgins CB.Comparative effects of ionic and nonionic contrast materials on coronary and peripheral blood flow.Invest Radiol,1982,17(3):292-298.
• [37]Hodgson JM,Williams DO.Superiority of intracoronary papaverine to radiographic contrast for measuring coronary flow reserve in patients with ischemic heart disease.Am Heart J,1987,114(4 Pt 1):704-710.
• [38]Tatineni S,Kern MJ,Deligonul U,et al.The effects of ionic and nonionic radiographic contrast media on coronary hyperemia in patients during coronary angiography.Am Heart J,1992,123(3):621-627.
• [39]Topcu S,Tanboga IH,Aksakal E,et al.Effi cacy of coronary f ractional f low reserve using contrast medium compared to adenosine.Postepy Kardiol Interwencyjnei,2016,12(3):212-216.
• [40]Leone AM,Scalone G,De Maria GL,et al.Effi cacy of contrast medium induced pd/pa ratio in predicting functional significance of intermediate coronary artery stenosis assessed by fractional fl ow reserve:insights from the RINASCI study.Euro Intervention,2015,11(4):421-427.
• [41]Cialdella P,D'Amario D,Leone AM.The ongoing search for simplifying fractional fl ow reserve assessment:the role of contrast medium.Postepy Kardiol Interwencyjnej,2016,12(3):197-199.
• [42]Hendel RC,Bateman TM,Cerqueira MD,et al.Initial clinical experience with regadenoson,a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.J Am Coll Cardiol,2005,46(11):2069-2075.
• [43]Miller DD.Impact of selective adenosine A2A receptor agonists on cardiac imaging feeling the lightning,waiting on the thunder.J Am Coll Cardiol,2005,46(11):2076-2078.
• [44]Nair PK,Marroquin OC,Mulukutla SR,et al.Clinical utility of regadenoson for assessing fractional fl ow reserve.JACC Cardiovasc Interv,2011,4(10):1085-1092.
• [45]Pijls NH,Tonino PA.The crux of maximum hyperemia.JACCCardiovasc Interv,2011,4(10):1093-1095.
• [46]van Nunen LX,Lenders GD,Schampaert S,et al.Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional fl ow reserve measurement.Euro Intervention,2015,11(8):905-913.
• [47]Stolker JM,Lim MJ,Shavelle DM,et al.Pooled comparison of regadenoson versus adenosine for measuring fractional fl ow reserve and coronary flow in the catheterization laboratory.Cardiovasc Revasc Med,2015,16(5):266-271.
• [48]Niccoli G,Burzotta F,Galiuto L,et al.Myocardial no-refl ow in humans.J Am Coll Cardiol,2009,54(4):281-292.
• [49]Bates JN,Baker MT,Guerra R Jr,et al.Nitric oxide generation from nitroprusside by vascular tissue.Evidence that reduction of the nitroprusside anion and cyanide loss are required.Biochem Pharmacol,1991,42 Suppl:S157-S165.
• [50]Parham WA,Bouhasin A,Ciaramita JP,et al.Coronary hyperemic dose responses of intracoronary sodium nitroprusside.Circulation,2004,109(10):1236-1243.
• [51]Martin-Reyes R,de la Torre Hernandez JM,Franco-Pelaez J,et al.The use of the acute Pd/Pa drop after intracoronary nitroglycerin infusion to rule out signifi cant FFR:CANICA(Can intracoronary nitroglycerin predict fractional flow reserve without adenosine?)multicenter study.Catheter Cardiovasc Interv,2016,87(2):262-269.
• [52]Israeli Z,Bagur R,Murariu D,et al.Nitroglycerin-derived Pd/Pa for the assessment of intermediate coronary lesions.J Invasive Cardiol,2017,29(12):E177-E183.
• [53]Jang HJ,Koo BK,Lee HS,et al.Safety and effi cacy of a novel hyperaemic agent,intracoronary nicorandil,for invasive physiological assessments in the cardiac catheterization laboratory.Eur Heart J,2013,34(27):2055-2062.
• [54]Oi M,Toyofuku M,Matsumura Y,et al.Utility of nicorandil for the measurement of coronary fractional flow reserve.Cardiovasc Interv Ther,2014,29(1):24-30.
• [55]Lee JM,Kato D,Oi M,et al.Safety and effi cacy of intracoronary nicorandil as hyperaemic agent f or invasive physiological assessment:a patient-level pooled analysis.Euro Intervention,2016,12(2):e208-e215.